Introduction
============

Smoking is the leading cause of preventable mortality world wide\[[@B1]\]. One in every 2 long-term smokers will die a smoking related death\[[@B2]\]. Stopping smoking has a considerable impact on improving life expectancy, reducing morbidity and reducing health care costs associated with treating smoking related conditions\[[@B3]\].

Several pharmacological interventions to assist in smoking cessation are available\[[@B4]\]. The most commonly used formulation is nicotine replacement therapy (NRT), frequently available over the counter (OTC). NRT is currently recommended as a safe intervention to general populations and higher-risk groups, including pregnant and breastfeeding women, adolescents, and smokers with cardiovascular disease\[[@B5]\]. NRT improves cessation rates at one year by approximately 70% (odds ratio \[OR\] 1.70, 95% Confidence Interval \[CI\] 1.55-1.88)\[[@B4],[@B6]\].

Available research suggests that smokers are less motivated to use NRT if they expect that it will cause mild adverse effects\[[@B7]\]. Published systematic reviews of NRT have not explicitly synthesized the incidence of side effects of NRT products. An understanding of the nature and likelihood of the most common side effects may help clinicians communicate to patients the benefits and risks associated with their use of NRT. This information may also improve selection of specific delivery mechanisms based upon patient history, which may improve treatment adherence. While RCTs provide strong information on causation of adverse events, observational studies may report on associations or hypotheses about more rare events. To determine the frequency and incidence of adverse events associated with NRT, we conducted a systematic review and meta-analysis of RCT\'s and observational studies of NRT in any delivery formulation. Our clinical question is, in patients receiving NRT for smoking cessation, compared to inert controls, what is the incidence of adverse events and what are those adverse events?

Methods
=======

Eligibility criteria
--------------------

We included RCTs of any duration beyond 4 weeks. RCTs had to compare NRT with an inert control (eg. placebo or standard of care). We chose 4 weeks to include the timeframe of maximum nicotine withdrawal symptoms so that adverse events may be differentiated from withdrawal symptoms\[[@B8]\]. We additionally sought out observational studies to examine the proportion of events occurring\[[@B9]\]. We evaluated adverse effects reported at any point in the duration of the studies. We included any form of NRT delivery (i.e. lozenge, skin patch, gum, nasal spray, inhaler, and tablet). We did not examine efficacy in this analysis. We excluded post-hoc analyses, maintenance therapy, or relapse prevention studies.

Search strategy
---------------

In consultation with a medical librarian, we established a search strategy. We searched independently, in duplicate, the following 10 databases (from inception to November 20, 2009): MEDLINE, EMBASE, Cochrane CENTRAL, AMED, CINAHL, TOXNET, Development and Reproductive Toxicology, Hazardous Substances Databank, Psych-info and Web of Science. Given that observational studies are poorly indexed in many databases, we also searched databases that include the full text of journals (*ScienceDirect*, and *Ingenta*, including articles in full text from approximately 1700 journals since 1993)\[[@B10]\]. In addition, we searched the bibliographies of published systematic reviews and health technology assessments\[[@B4]-[@B6],[@B11]-[@B16]\]. Searches were not limited by language, sex or age.

Study selection
---------------

Two investigators (EM, PW) working independently, in duplicate, scanned all abstracts and obtained the full text reports of records indicating that the study was either an RCT or observational study evaluating NRT on the outcomes of interest. After obtaining full reports of the candidate studies (either in full peer-reviewed publication or press article) the same reviewers independently assessed eligibility via full text review.

Data collection
---------------

Two reviewers (EM, PW) conducted data extraction independently using a standardized pre-piloted form. Reviewers collected information about the NRT intervention tested, the population studied (age, sex, underlying conditions), treatment dosages and dosing schedules, the specific measurement of abstinence (prolonged or point-prevalence), and the methods of biochemical confirmation. The reviewers extracted data on adverse events characterized by the study authors as physical or mental adverse events. Recognizing that adverse events may include both physical and mental effects concomitantly, we defined physical adverse events as effects confined to physical parts of the body and mental adverse events as symptoms accompanied by psychological conditions. We characterized serious adverse events as unexpected life-threatening events occurring during the trial period. *A priori*, we examined the follow life-threatening adverse events: all-cause mortality, myocardial infarction, all-cause strokes, incidence of all-cancers, all-hospitalizations, suicidal ideation, depression, and incidence of diabetes. Study quality evaluation included general methodological reporting features including allocation concealment, sequence generation, blinding status, intention-to-treat, and appropriate descriptions of loss to follow-up. In rating quality, failure to report a quality component of study design (e.g. blinding) was treated the same as not employing it. We entered the data into an electronic database such that duplicate entries existed for each study. When the two entries did not match, we resolved differences through discussion and consensus. In the absence of an inert control group, we considered randomized NRT dosing studies to be observational studies and collected data on proportion of combined events. For cohort studies, we additionally calculated events as proportions of events.

Data analysis
-------------

In order to assess inter-rater reliability on inclusion of articles, we calculated the *Phi*statistic (*ϕ*), which provides a measure of inter-observer agreement independent of chance\[[@B17]\]. We calculated the Odds Ratios \[OR\] and appropriate 95% Confidence Intervals \[CIs\] of outcomes according to the number of events reported in the original studies or sub-studies. Given that zero events in one treatment arm prevents a useful ratio from being developed, in circumstances of zero outcome events in one arm of a trial, we added 0.5 to each arm, as suggested by Sheehe\[[@B18]\]. We first pooled studies of all NRT interventions versus all controls using the DerSimonian-Laird random effects method\[[@B19]\], which recognizes and anchors studies as a sample of all potential studies, and incorporates an additional between-study component to the estimate of variability\[[@B20]\]. We calculated the I^2^ statistic for each analysis as a measure of the proportion of the overall variation that is attributable to between-study heterogeneity\[[@B21]\]. Given that we are examining adverse events, interpreting heterogeneity estimates can be challenging as even pooled analysis with large heterogeneity may provide important insights into the likelihood of events\[[@B9]\]. We considered an I^2^above 50% as moderate to large heterogeneity and examined explanations of heterogeneity by applying a random effects meta-regression with the following co-variates: oropharyngeal formulation vs. skin patch; duration of study (in months); reporting of allocation concealment, and reporting of blinding status. We then calculated the residual heterogeneity and present it as the residual I^2^. Forest plots are displayed for each primary analysis, showing pooled study effect measures with 95% CIs, and the overall DerSimonian-Laird pooled estimate. For studies considered as observational studies, we calculated pooled weighted proportions by first stabilizing the variances of the raw proportions (r/n) using a Freeman-Tukey type arcsine square root transformation and applying a random effects model. While several methods of pooling proportions exist, the Freeman-Tukey method works well with both fixed and random effects meta-analysis and truncates at zero\[[@B22]\]. This is a variance-stabilizing transformation that removes the dependence of the variance on the mean of the transformed proportion (ie. it corrects for overdispersion). Assessing heterogeneity in pooled proportions may be misleading\[[@B23],[@B24]\], therefore we report the I^2^value, as this measure is less affected by the number of studies as the more commonly used I^2^. The square root of this number (i.e. tau \[***τ***\]) is the estimated standard deviation of underlying effects across studies\[[@B25]\]. As with the RCT analysis, we applied a random-effects meta-analysis. Analyses were conducted using StatsDirect (version 2.5.2) and Comprehensive Meta-analysis (version 2).

Results
=======

Study inclusion and methods reporting (Figure [1](#F1){ref-type="fig"})
-----------------------------------------------------------------------

![**low-diagram of included studies**.](1617-9625-8-8-1){#F1}

One hundred and twenty studies met our inclusion criteria (ϕ = 0.91) \[[@B26],[@B110]-[@B141]\]. Figure [1](#F1){ref-type="fig"} displays the search break-down. Additional file [1](#S1){ref-type="supplementary-material"} and Table [1](#T1){ref-type="table"} provide study characteristics. Ninety-two studies\[[@B26]-[@B117]\] were RCTs involving 32,185 participants and 28\[[@B56],[@B75],[@B93],[@B110],[@B118]-[@B141]\] were considered as observational studies involving 145, 205 participants.

###### 

Characteristics of nicotine replacement therapy (NRT) observational studies

  Author              Country          Participants            Cigarettes per day \*(mean, median)   Years Smoking \*(mean, median)   Intervention                              Dosage (mg)                 Number treated   co-intervention                     Duration of treatment
  ------------------- ---------------- ----------------------- ------------------------------------- -------------------------------- ----------------------------------------- --------------------------- ---------------- ----------------------------------- -----------------------
  Hilleman, 1994      USA              Healthy                 26\*                                  ≥ 3                              Patch (fixed dosage)                      21                          69               Education session                   12 weeks
                                                                                                                                      Patch (tapered dose)                      7,14,21                     71                                                   
  Orleans, 1994       USA              Older adults            17\*                                  50\*                             Patch                                     7,14,21                     871              Counseling                          12 weeks
  Fredrickson, 1995   USA              Healthy                 \>20                                  28\*                             Patch                                     22,44                       40               Counseling                          8 weeks
  Herrera, 1995       Sweden           Healthy                 ≥ 10                                  NA                               Gum                                       2,4                         167              Behavioural modification program    3 months
  Jorenby, 1995       USA              Healthy                 27\*                                  1                                Patch                                     22,44                       504              Counseling                          8 weeks
  Martin, 1995        New Zealand      Healthy and unhealthy   26\*                                  10\*                             Patch                                     7,14,21                     80               Counseling                          12 weeks
  Smith, 1995         USA              Healthy and unhealthy   26\*                                  20\*                             Patch                                     7,14,21                     110              Counseling                          12 weeks
  Smith, 1996         USA              Adolescent              23\*                                  2.6\*                            Patch                                     11,22                       22               Counseling                          8 weeks
  Hurt, 1998          USA              Healthy                 28\*                                  22\*                             Nasal spray                               1-2 mg/h                    50               Counseling                          8 weeks
  Gourlay, 1999       Australia        Healthy                 ≥ 15                                  ≥ 3                              Patch                                     21                          1481             Counseling                          12 weeks
  Hays, 1999          USA              Healthy                 ≥ 15                                  ≥ 1                              Patch                                     22                          315              None                                6 weeks
  Killen, 1999        USA              Healthy                 35\*                                  NA                               Patch                                     15 or 25                    408              Self-treatment booklet              6 weeks
  Hurt, 2000          USA              Adolescent              20\*                                  \>1                              Patch                                     15                          101              Counseling                          6 weeks
  Shiffman, 2002      USA              Healthy                 27\*                                  24\*                             Patch                                     7,14,21                     2367             None                                12 weeks
                                                               27\*                                  23\*                             Gum                                       2,4                         2981             None                                12 weeks
  Croghan, 2003       USA              Healthy                 ≥ 15                                  ≥ 1                              Patch, Nasal spray, Patch + Nasal spray   15 mg/patch, 0.5 mg/spray   1384             Behavioural counseling              6 weeks
  Hasford, 2003       Germany          Healthy and unhealthy   NA                                    19\*                             Patch                                     7,14,21                     633              None                                12 weeks
  Carpenter, 2004     USA              Healthy                 ≥ 10                                  NA                               Patch                                     7,14,21                     300              Reduction counseling                6 weeks
  Fiore, 2004         USA              Healthy                 ≥ 10                                  NA                               Patch                                     7,14, 21                    1869             With or without education program   10 weeks
  Lerman, 2004        USA              Healthy                 ≥ 10                                  1                                Patch, Nasal spray                        0.5, 7-21                   350              Counseling                          8 weeks
  Schuurmans, 2004    South Africa     Healthy                 ≥ 15                                  ≥ 3                              Patch                                     NA                          184              None                                10 weeks
  Hughes, 2005        USA              Healthy and unhealthy   25\*                                  27\*                             Nasal spray                               NA                          535              None                                4 weeks
  Marsh, 2005         Czech Republic   Medical illness         25\*                                  ≥ 1                              Gum, Lozenge                              4                           901              None                                12 weeks
  Bolliger, 2007      South Africa     Healthy                 23\*                                  23\*                             Gum, Patch, Nasal spray                   NA                          100              Behavioural counseling              3 months
  Aubin, 2008         USA              Healthy                 23\*                                  25\*                             Patch                                     7,14,21                     370              Counseling                          10 weeks
  Stapleton, 2008     UK               Healthy and unhealthy   21\*                                  NA                               NRT                                       NA                          204              Education session                   12 weeks
  Gunnell, 2009       Europe           Healthy and unhealthy   NA                                    NA                               NRT                                       NA                          63265            None                                12-26 weeks
  Ossip, 2009         USA              Healthy and unhealthy   NA                                    NA                               Gum, Patch, Lozenge                       2,7-21,2                    65599            None                                2 weeks
  Steinberg, 2009     USA              Medical illnesses       \>10                                  \>20                             Patch                                     7,14,21                     64               None                                10 weeks

Of RCTs, eighty-three \[[@B26]-[@B34],[@B37],[@B66],[@B105]-[@B109],[@B65]-[@B85],[@B87]-[@B90],[@B92]-[@B97],[@B99]-[@B102],[@B112],[@B114]-[@B117],[@B142]\](83/92) used a placebo control. Forty-two\[[@B39]-[@B41],[@B43],[@B45],[@B47]-[@B49],[@B51]-[@B55],[@B60],[@B61],[@B64],[@B66],[@B68]-[@B72],[@B74]-[@B77],[@B81],[@B83],[@B87],[@B89],[@B90],[@B92],[@B93],[@B98],[@B99],[@B102],[@B103],[@B105]-[@B107],[@B112],[@B115]\] evaluated the nicotine patch; 26\[[@B26]-[@B38],[@B42],[@B56],[@B58],[@B79],[@B88],[@B95],[@B100],[@B101],[@B108],[@B109],[@B113],[@B116],[@B142]\] the nicotine gum; 6 \[[@B44],[@B50],[@B57],[@B65],[@B73],[@B111]\]the nicotine nasal spray; 6\[[@B46],[@B62],[@B63],[@B67],[@B78],[@B96]\] the nicotine inhaler; 4 \[[@B80],[@B84],[@B97],[@B114]\]the nicotine tablet; 1\[[@B85]\] the nicotine lozenge; and, the remainder (n = 35) evaluated NRT combination therapies. Duration of treatment ranged from 1 to 24 months, with varying levels of dosages for each form of NRT.

Seventy-four RCTs\[[@B26]-[@B31],[@B33]-[@B41],[@B43]-[@B65],[@B67]-[@B70],[@B72]-[@B80],[@B82]-[@B88],[@B92],[@B93],[@B95],[@B96],[@B99]-[@B101],[@B103],[@B106]-[@B109],[@B114]-[@B117]\] were conducted in healthy adult populations. An additional 6\[[@B36],[@B66],[@B89],[@B97],[@B105],[@B113]\] were conducted among populations with medical and psychiatric co-morbidities (.eg. smoking-related diseases, chronic diseases, alcoholism, depression), 4\[[@B81],[@B98],[@B104],[@B142]\] among pregnant women, 3\[[@B42],[@B71],[@B91]\] among hospitalized patients, 3\[[@B90],[@B94],[@B111]\] among adolescents, 1 \[[@B102]\]among postmenopausal women, and 1\[[@B112]\] among surgical patients. Fifty-nine \[[@B27]-[@B30],[@B33],[@B36]-[@B38],[@B41],[@B42],[@B45],[@B48]-[@B56],[@B58],[@B59],[@B61]-[@B63],[@B66],[@B67],[@B71],[@B73],[@B74],[@B76],[@B77],[@B79],[@B81],[@B83],[@B86],[@B89]-[@B92],[@B94],[@B97]-[@B102],[@B104]-[@B108],[@B111],[@B113]-[@B117],[@B142]\]RCTs included co-interventions, of which 20\[[@B27],[@B36],[@B49]-[@B52],[@B54],[@B61],[@B71],[@B79],[@B81],[@B91],[@B98],[@B100]-[@B102],[@B111],[@B114],[@B116],[@B117]\] provided general counseling (eg. group counseling or individual counseling), 19\[[@B28],[@B41],[@B53],[@B56],[@B61],[@B63],[@B67],[@B76],[@B85],[@B89],[@B90],[@B92],[@B94],[@B99],[@B104]-[@B107],[@B113]\] provided behavioural or psychological treatment, 12\[[@B29],[@B30],[@B33],[@B37],[@B42],[@B45],[@B55],[@B62],[@B66],[@B74],[@B86],[@B97]\] provided varying forms of advice or support, 3\[[@B38],[@B108],[@B142]\] provided educational sessions, 4\[[@B58],[@B59],[@B73],[@B77]\] provided an additional NRT and/or placebo, and 1\[[@B115]\] provided rimonabant, an endocannabinoid antagonist used as an appetite suppressant.

Seventeen observational studies\[[@B75],[@B93],[@B110],[@B119]-[@B124],[@B126]-[@B129],[@B131]-[@B133],[@B141]\] used the nicotine patch; 2 \[[@B125],[@B135]\]used a nasal spray, 1\[[@B129]\] used the nicotine gum; and 8 used a combination of NRTs. Duration of treatment ranged from 4 to 26 weeks, with varying levels of dosages for each form of NRT. Sixteen\[[@B56],[@B75],[@B93],[@B110],[@B118],[@B122],[@B123],[@B125]-[@B127],[@B129],[@B130],[@B132]-[@B134],[@B137]\] of the observational studies were conducted among healthy adult populations, 7 \[[@B120],[@B121],[@B131],[@B135],[@B138]-[@B140]\]among mixed healthy and unhealthy adult populations, 2\[[@B136],[@B141]\] among adult populations with medical co-morbidities, 2\[[@B124],[@B128]\] among adolescent populations, and 1\[[@B119]\] among an older adult population. The majority of observational studies\[[@B110],[@B119],[@B128],[@B133],[@B134],[@B56],[@B118],[@B127],[@B130],[@B132],[@B137],[@B138]\](19/28) included co-interventions, with 12\[[@B110],[@B119]-[@B126],[@B128],[@B133],[@B134]\] providing general counseling; 3\[[@B56],[@B130],[@B137]\] providing counseling specific to behaviour or behaviour modification; 3\[[@B118],[@B132],[@B138]\] providing educational sessions; and 1 \[[@B127]\]providing a self-help booklet.

Studies reported methodological issues variably. Thirty-eight RCTs\[[@B28],[@B29],[@B31],[@B37],[@B41],[@B44],[@B46],[@B59],[@B61]-[@B63],[@B65],[@B70]-[@B75],[@B77],[@B78],[@B81],[@B82],[@B84],[@B85],[@B90],[@B93],[@B97]-[@B99],[@B101],[@B102],[@B104],[@B105],[@B112],[@B115]-[@B117],[@B142]\] reported sequence generation of randomization; 17\[[@B28],[@B29],[@B31],[@B37],[@B59],[@B63],[@B67],[@B69],[@B71],[@B73]-[@B75],[@B81],[@B93],[@B98],[@B99],[@B115]\] reported allocation concealment; and, 81\[[@B26]-[@B34],[@B37],[@B66],[@B105]-[@B107],[@B109],[@B65]-[@B80],[@B82]-[@B85],[@B87]-[@B90],[@B92]-[@B97],[@B99]-[@B102],[@B112],[@B114]-[@B117],[@B142]\] reported on patient blinding in the study. To confirm smoking abstinence, eighty four\[[@B26]-[@B28],[@B30]-[@B46],[@B48],[@B66],[@B105],[@B107]-[@B109],[@B65],[@B67],[@B69]-[@B80],[@B83]-[@B98],[@B100]-[@B104],[@B111],[@B112],[@B114]-[@B117],[@B142]\] studies used exhaled carbon monoxide (CO); 16\[[@B34],[@B35],[@B37],[@B41],[@B45],[@B55],[@B57],[@B62],[@B63],[@B79],[@B81],[@B90],[@B94],[@B107],[@B111],[@B142]\] used salivary cotinine; 5\[[@B29],[@B36],[@B47],[@B60],[@B101]\] used serum cotinine; and 2\[[@B99],[@B114]\] used urinary cotinine. No studies required participants to pay for the NRT. In 80 studies, \[[@B26]-[@B29],[@B31]-[@B41],[@B43]-[@B54],[@B56],[@B66],[@B105]-[@B109],[@B113],[@B65],[@B68],[@B70]-[@B72],[@B74]-[@B77],[@B79],[@B80],[@B83]-[@B87],[@B89],[@B90],[@B92]-[@B94],[@B97]-[@B104],[@B111],[@B112]-[@B117],[@B142]\] participants were planning on quitting. All observational studies are considered as non-comparative single-arm studies reporting prevalence of the adverse events in the community.

### Adverse events

RCTs (See Figure [2](#F2){ref-type="fig"})
------------------------------------------

![Summary pooled estimates of adverse events reported in RCTs](1617-9625-8-8-2){#F2}

We evaluated all forms of NRT for adverse events. Additional file [1](#S1){ref-type="supplementary-material"} displays the study characteristics and table [2](#T2){ref-type="table"} displays the RCT findings.

###### 

Adverse events reported in RCTs

  Adverse event                             RCTs   References                                                                                                                                                                              *n*treatment having event   Total *n*in treatment   *n*control having event   Total *n*in control   OR     95% CI       P-value   **I**^**2**^
  ----------------------------------------- ------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------- ----------------------- ------------------------- --------------------- ------ ------------ --------- --------------
  Headache                                  32     \[[@B27],[@B33]-[@B35],[@B41],[@B43]-[@B45],[@B48],[@B50],[@B51],[@B55],[@B57],[@B58],[@B61],[@B64],[@B68],[@B71],[@B74]-[@B76],[@B85],[@B90],[@B94],[@B95],[@B103],[@B115],[@B117]\]   938                         9227                    664                       5988                  0.99   0.84-1.17    0.95      43%
  Dizziness                                 24     \[[@B37]-[@B39],[@B41],[@B45]-[@B48],[@B51],[@B53],[@B58],[@B60],[@B64],[@B72],[@B73],[@B78],[@B92],[@B96],[@B117],[@B119]\]                                                            414                         4701                    275                       3518                  1.05   0.86-1.29    0.59      18%
  Heart palpitations and chest pains        12     \[[@B32],[@B44],[@B45],[@B50],[@B57],[@B61],[@B68],[@B71],[@B74],[@B75],[@B102],[@B116]\]                                                                                               189                         6249                    64                        3985                  2.06   1.51-2.82    \<0.001   0%
  Nausea or vomiting                        31     \[[@B24],[@B27],[@B31],[@B37]-[@B39],[@B45]-[@B48],[@B51],[@B53],[@B56],[@B58],[@B59],[@B62],[@B68],[@B71],[@B74]-[@B76],[@B85],[@B90],[@B94],[@B95],[@B103],[@B115]\]                  747                         7249                    388                       6061                  1.67   1.37-2.04    \<0.001   62%
  Indigestion Gastrointestinal complaints   26     \[[@B27],[@B28],[@B32],[@B35],[@B37],[@B42],[@B43],[@B45],[@B51],[@B58],[@B63],[@B68],[@B70],[@B71],[@B80],[@B84],[@B85],[@B90],[@B94],[@B95],[@B105],[@B116],[@B117]\]                 930                         8575                    489                       5882                  1.54   1.25-1.89    \<0.001   35%
  Skin irritation                           32     \[[@B39]-[@B41],[@B43],[@B45],[@B47],[@B48],[@B51],[@B53]-[@B55],[@B58],[@B59],[@B61],[@B64],[@B66],[@B68]-[@B72],[@B74]-[@B77],[@B87],[@B90],[@B93],[@B94],[@B102],[@B105],[@B117]\]   1550                        8646                    511                       5497                  2.80   2.28-3.44    \<0.001   0%
  Arthralgia                                5      \[[@B43],[@B45],[@B61],[@B70],[@B90]\]                                                                                                                                                  50                          756                     34                        686                   1.51   0.87-2.63    0.13      0%
  Hiccoughs                                 14     \[[@B27],[@B32],[@B34],[@B35],[@B37],[@B38],[@B63],[@B80],[@B83],[@B84],[@B94],[@B95],[@B117]\]                                                                                         934                         3858                    573                       3424                  7.68   4.59-12.85   \<0.001   0%
  Mouth and throat soreness                 23     \[[@B27],[@B31]-[@B35],[@B37],[@B42],[@B44],[@B46],[@B50],[@B57],[@B63],[@B67],[@B78],[@B80],[@B84],[@B85],[@B94]-[@B96],[@B117]\]                                                      935                         3858                    573                       3424                  1.87   1.36-2.57    \<0.001   66%
  Mouth ulcers                              6      \[[@B27],[@B33]-[@B35],[@B63],[@B84]\]                                                                                                                                                  123                         61                      766                       610                   1.49   1.05-2.20    0.02      43%
  Urticaria                                 3      \[[@B48],[@B70],[@B90]\]                                                                                                                                                                80                          801                     66                        595                   1.13   0.77-1.65    0.52      0%
  Coughing                                  12     \[[@B44],[@B50],[@B57],[@B63],[@B67],[@B78],[@B79],[@B83],[@B84],[@B94],[@B116]\]                                                                                                       583                         3989                    309                       3893                  2.89   1.92-4.33    \<0.001   72%
  Insomnia                                  19     \[[@B27],[@B28],[@B32],[@B35],[@B37],[@B42],[@B43],[@B45],[@B51],[@B58],[@B63],[@B68],[@B70],[@B71],[@B80],[@B84],[@B85],[@B90],[@B94],[@B95],[@B105],[@B116],[@B117]\]                 636                         5805                    349                       3504                  1.42   1.21-1.66    \<0.001   65%
  Sweating                                  3      \[[@B44],[@B50],[@B57]\]                                                                                                                                                                56                          355                     63                        337                   1.29   0.51-3.21    0.58      76%
  Anxiety                                   6      \[[@B71],[@B76],[@B94],[@B103],[@B115]\]                                                                                                                                                25                          367                     21                        362                   1.24   0.73-2.10    0.42      0%
  Depression                                9      \[[@B43],[@B45],[@B58],[@B64],[@B71],[@B94],[@B102],[@B103],[@B115]\]                                                                                                                   56                          937                     59                        897                   0.82   0.53-1.26    0.37      8%
  Mortality                                 8      \[[@B73],[@B82],[@B85],[@B93],[@B97],[@B105],[@B113],[@B115]\]                                                                                                                          11                          1387                    16                        1378                  0.74   0.33-1.67    0.47      0%

### Cardiovascular and respiratory

A pooled analysis of 12 RCTs found a statistically significant increased risk for heart palpitations and chest pains associated with NRT (OR 2.06, 95% CI, 1.51-2.82, p \< 0.001; I^2^= 0%). Applying meta-regression, both the nicotine patch and orally administered NRT were associated with an increased risk (OR 1.11, 95% CI, 0.53-2.33, P = 0.75). Coughing was significantly elevated in 12 RCTs (OR 2.89, 95% CI, 1.92-4.33, P =\< 0.001; I^2^= 72%), but was associated with considerable heterogeneity.

### Gastrointestinal

There was a statistically significant increased risk of nausea or vomiting based on a pooled analysis of 31 RCTs (OR 1.67, 95% CI, 1.37-2.04, P =\< 0.001; I^2^= 62%). However, meta-regression showed that studies focusing on the nicotine patch were associated with a decreased risk (OR, 0.73, 95%, 0.56-0.97, P = 0.029) of nausea and vomiting. The review also found an increased risk of indigestion and general GI complaints with NRT in an analysis of 26 RCTs (OR 1.54, 95% CI 1.25-1.89, p \< 0.001; I^2^= 35%). Using only orally administered NRT caused significantly greater risk for GI complaints compared with the nicotine patch (OR 1.66, 95% CI, 1.04-2.63, P = 0.03), and was also associated with an increased risk of hiccoughs (see Table [2](#T2){ref-type="table"}).

### Oral

A significantly heightened risk of oral adverse events including mouth and throat soreness was identified in a meta-analysis of 23 RCTs (OR 1.87, 95% CI, 1.36-2.57, P \< 0.001; I^2^= 66%). A meta-analysis of 6 RCTs found a significantly elevated risk for mouth ulcers (OR 1.49, 95% CI, 1.05-2.20, P = 0.02; I^2^= 43%).

### Neurological

A meta-analysis of 32 RCTs (Table [2](#T2){ref-type="table"}) found that headache was not associated with NRT use (P = 0.65; I^2^= 43%), while an analysis of 24 RCTs, found no association between NRT use and increased dizziness (P = 0.59; I^2^= 18%)

### Dermatological

Nicotine patch was associated with a statistically significant risk of skin irritation in an analysis of 32 RCTs (OR 2.80, 95% CI, 2.28-3.44, P \< 0.001; I^2^= 0%). However, nicotine patch was not associated with increased incidence of urticaria (OR 1.13, 95% CI, 0.77-1.65, P = 0.52; I^2^= 0%) or sweating (OR 1.29, 95% CI, 0.51-3.21, P = 0.58; I^2^= 76%).

### Psychological

An increased risk of insomnia was associated with the nicotine patch (OR 1.42, 95% CI, 1.21-1.66, P \< 0.001; I^2^= 65%). Anxiety and depression were, however, not significantly increased (see Table [2](#T2){ref-type="table"}).

### Serious Adverse Events

Twenty five RCTs\[[@B47],[@B54],[@B71],[@B73]-[@B77],[@B79],[@B80],[@B82],[@B84],[@B85],[@B91]-[@B93],[@B97],[@B98],[@B100],[@B102],[@B104],[@B105],[@B113],[@B115],[@B142]\] reported serious adverse events occurring, but none were statistically significant (data not shown). Eight studies\[[@B73],[@B82],[@B85],[@B93],[@B97],[@B105],[@B113],[@B115]\] reported on mortality by groups and did not find a significant association between NRT and controls. One study\[[@B142]\] of pregnant women found two cases of spontaneous abortions in the NRT group and one study\[[@B76]\] reported a case of spinal meningitis in the NRT group.

Explanations of heterogeneity
-----------------------------

We used meta-regression to explain heterogeneity. We found large heterogeneity (I^2^= 62%) in our analysis of pooled events of nausea and vomiting. We were able to explain a large amount of heterogeneity examining the covariate of skin patch vs. oropharyngeal administration (OR 0.73, 95% CI, 0.56-0.97, P = 0.02, I^2^= 42%) as well as reporting of allocation concealment (OR 1.50, 95% CI, 1.07-1.59, P = 0.002, I^2^= 37%). We also found large heterogeneity (I^2^= 66%) in the event of mouth and throat soreness, but were unable to explain this using our pre-specified covariates. Considerable heterogeneity (I^2^= 72%) was also identified for the adverse event of coughing. We found that duration of study (*B*coefficient 0.07, 95% CI, 0.01-0.12, P = 0.01, I^2^= 42%) and allocation concealment (OR 0.53, 95% CI, 0.31-0.91, P = 0.02, I^2^= 43%) contributed to heterogeneity observed in this analysis. Our analysis of sweating found large heterogeneity (76%) that was predominantly contributed by a study that provided concomitant bupropion, indicating that the dual use of both drugs resulted in a significantly higher incidence of sweating (OR 29.24, 95% CI, 3.96-215.48). We also found heterogeneity in our analysis of insomnia that was explained by the duration of the trials. Longer duration trials had reduced rates of insomnia (*B*coefficient -0.07, 95% CI, -0.13 to -0.008, p = 0.02).

### Observational studies (See Figure [3](#F3){ref-type="fig"})

![**Summary pooled estimates of adverse events reported in observational studies**.](1617-9625-8-8-3){#F3}

Table [1](#T1){ref-type="table"} displays the study characteristics of the observational studies. No studies compared NRT with an inert control group, thus we present the proportions of event occurrence, interpreted as prevalence. As our analysis uses pooled proportions, all analyses found an estimate of risk, but varied in magnitude. Table [3](#T3){ref-type="table"} presents the study findings.

###### 

Adverse events reported in observational studies

  Adverse event                 Number of studies   References                                                                                                          N of events   Pooled n   Proportion   95% CI      ***τ***^**2**^
  ----------------------------- ------------------- ------------------------------------------------------------------------------------------------------------------- ------------- ---------- ------------ ----------- ----------------
  Headache                      17                  \[[@B75],[@B93],[@B110],[@B118]-[@B120],[@B123]-[@B125],[@B127]-[@B129],[@B131],[@B136],[@B138],[@B140],[@B141]\]   1472          75764      9.7          4.6-19.5    2.97
  Nausea or vomiting            14                  \[[@B75],[@B110],[@B119],[@B120],[@B123],[@B124],[@B128],[@B129],[@B136]-[@B138],[@B140],[@B141]\]                  1902          74449      8.5          4.6-15.3    1.39
  Gastrointestinal complaints   11                  \[[@B110],[@B118],[@B120],[@B123],[@B127],[@B129],[@B131],[@B136],[@B138],[@B140],[@B141]\]                         593           74256      3.9          1.4-10.4    3.02
  Heart palpitations            7                   \[[@B75],[@B120],[@B122],[@B127],[@B131],[@B136],[@B141]\]                                                          72            2446       3.6          1.4-9.0     1.49
  Mouth and throat soreness     6                   \[[@B125],[@B129],[@B135]-[@B137],[@B140]\]                                                                         406           72533      5.4          0.9-25.6    5.00
  Skin irritation               16                  \[[@B75],[@B93],[@B118]-[@B124],[@B126]-[@B129],[@B131],[@B138],[@B141]\]                                           1337          10356      19.5         11.5-31.1   1.56
  Hiccoughs                     4                   \[[@B129],[@B136],[@B137],[@B140]\]                                                                                 375           71948      2.5          0.3-16.5    4.63
  Coughing                      5                   \[[@B120],[@B125],[@B128],[@B135],[@B136]\]                                                                         125           1672       8.1          2.1-26      2.29
  Depression                    6                   \[[@B110],[@B120],[@B124],[@B138],[@B140],[@B141]\]                                                                 69            66344      2.6          0.2-27      10.57
  Anxiety                       5                   \[[@B118],[@B120],[@B129],[@B138],[@B141]\]                                                                         104           5841       2.9          0.8-9.8     1.70
  Insomnia                      18                  \[[@B75],[@B110],[@B118]-[@B123],[@B125]-[@B129],[@B131],[@B138],[@B140],[@B141]\]                                  2262          76169      11.4         4.8-24.6    4.05
  Dizziness                     8                   \[[@B110],[@B118],[@B120],[@B124],[@B127],[@B129],[@B136],[@B141]\]                                                 299           7338       7.3          3.7-13.9    0.94
  Self-harm                     1                   \[[@B110],[@B118],[@B120],[@B124],[@B127],[@B129],[@B136],[@B141]\]                                                 141           63265      0.2          0-8.4       NA

### Cardiovascular or respiratory

The prevalence of heart palpitations and chest pains were reported sporadically and amounted to 3.6% of the populations examined. Coughing was reported as a prevalence of 8.1%.

### Gastrointestinal

In keeping with the RCT evidence indicating significant increases in specific events, the pooled observational evidence reported the nausea and vomiting prevalence to be 8.5% amongst individuals in the community treated with NRT. The prevalence of indigestion and other gastrointestinal complaints was 3.9%. Hiccoughs were a very common complaint in the RCT evidence, but poorly reported in the observational studies with a prevalence of just 2.5%.

### Oral

With orally administered NRT, the prevalence of both mouth and throat soreness was 5.4%.

### Psychological and neurological

For psychological complaints, the prevalence of insomnia was 11.4%. Anxiety and depression were more rarely reported (2.9% and 2.6% respectively). Dizziness was a more common complaint, with a prevalence of 7.3%. Headaches were commonly reported (9.7%).

### Dermatological

The prevalence of skin irritations associated with nicotine patch was reported as 19.5% of the populations examined.

### Serious adverse events

Serious adverse events were poorly reported in the observational studies. However, one study reported on a case of transient visual field impairment; one right-hemisphere stroke; one myocardial infraction; and one urticarial reaction from skin patch with symptoms of angiodema. Finally, in a single large observational study of self-harm (n = 63,265), 141 cases of fatal and non-fatal self-harm cases were identified (0.2%), in addition to 30 cases of suicidal ideation\[[@B139]\].

Discussion
==========

Principal Findings
------------------

This review found that NRT is associated with an increased risk of gastrointestinal complaints and insomnia. There was also an observed increased risk of skin irritation with the nicotine patch and oropharyngeal complaints with orally administered NRT. Although NRT was associated with an increased risk of heart palpitations, the review did not observe an increased incident of heart attack or death. With the exception of insomnia, NRT does not appear to be associated with serious adverse psychiatric effects.

The reviewers actively sought serious adverse events. The most serious adverse event consistently reported in both RCTs and observational studies were heart palpitations and chest pains (OR 2.06, 95% CI, 1.51-2.82, P \< 0.001). NRT has been implicated in reports of atrial fibrillation and myocardial infarction among patients with risk factors\[[@B143]-[@B148]\]. Several possible explanations for this exist. First, among patients using NRT who continue to smoke, high serum concentrations may stimulate the sympathetic nervous system, so increasing blood pressure, stroke volume and cardiac output\[[@B149]\]. Second, previous and current smokers may have established cardiovascular disease. Patients with unstable coronary syndrome, a common manifestation of coronary artery disease, may have unrecognized recent plaque ruptures including coronary vasoconstriction and increased strain placed on the heart due to tachycardia and hypertension\[[@B143]\]. Unofficial guidelines\[[@B149]\] caution the continued use of NRT in patients with known cardiovascular disease in the absence of a physician. They recommend that patients be warned of these risks and counseled to desist smoking and arrange intensive behavioral support\[[@B149]\]. In our analysis, we did not observe an increased risk for myocardial infarction or death from NRT.

Almost all studies demonstrated localized irritation related to NRT use, skin irritation with the use of NRT patch and mouth soreness and ulcerations with orally administered NRT. It is possible this is due to the success of cessation rather than NRT as mouth ulcers occur in about 40% of all individuals achieving tobacco abstinence regardless of cessation intervention\[[@B150]\]. It has previously been understood that mouth lesions are associated with smoking cessation and not NRT\[[@B150]\]. However, this review found a significantly increased risk of mouth ulcers with orally administered NRT users compared to inert controls who had ceased smoking. In order to prevent relapse due to treatment discontinuation, strategies should be developed to assist patients unable to continue oral administered NRT due to mouth ulcers such as increasing the nicotine patch dose, using the nicotine nasal spray, or switching to an alternative form of smoking cessation pharmacotherapy such as buproprion or varenicline.

Psychological adverse events, particularly suicidal ideation, are a major concern in patients initiating smoking cessation\[[@B151]\]. We found only one large retrospective observational study that discussed this topic and reported no significant difference in fatal and non-fatal self-harm associated with NRT compared to other frequently used pharmacotherapies, bupropion (HR 1.17, 95% CI, 0.59-2.32) or varenicline (HR 1.12, 95% CI, 0.67-1.88)\[[@B139]\].

A criticism of smoking cessation trials has been that they infrequently enroll participants with psychological difficulties, thus making generalizable statements about their safety difficult\[[@B152]\]. The present review found that 56 RCTs specifically excluded participants with mental disorders. Only two RCTs targeting participants with concomitant psychological difficulties, specifically alcoholism and depression, were identified\[[@B89],[@B92]\]. In these studies, the risk of insomnia was higher among those taking NRT, compared to controls, (OR 1.42, 95% CI, 1.21-1.66, P \< 0.001). Sleep disturbance can significantly worsen psychological distress and mental illness and impair quality of life\[[@B153]\]. Therefore, clinicians should remain vigilant about NRT-related sleep disturbance among patients with a history of psychiatric illness.

An important issue to examine when describing adverse events from smoking cessation therapies is whether the adverse events are related to a pharmacotherapy or whether they are related to tobacco withdrawal\[[@B154]\]. For example, insomnia and sleep disturbances could be related to tobacco abstinence. One way to assess this affect would be to compare side effects in those that have quit smoking in both groups. However, since individuals that quit smoking may differ from those that continue, this analysis would remove the benefits of randomization and introduce bias.

Limitations
===========

Our review has several limitations. These include limitations of the primary studies themselves as well as those associated with combining results across potentially heterogeneous studies or populations. The main limitation of the primary studies is the mechanism by which adverse events are recorded. In the majority of instances this would be through passive reporting and therefore be susceptible to the underreporting associated with such techniques. The majority of our analyses had low or moderate heterogeneity, although a few had high levels of heterogeneity. Pooling proportions always results in large estimates of heterogeneity and statistical techniques do not yet exist to interpret the extent of real between-study heterogeneity\[[@B155]\]. The review identified some discrepancies between observational studies and RCTs in terms of adverse event reporting. Possible explanations of this include the use of a control group in the RCTs, which diminishes the impact of adverse events that are, in fact, unrelated to the intervention. Studies included in our review varied in the duration of treatment phase. While we would expect most adverse events to occur during the treatment phase (receiving active NRT), it is possible that some adverse events occurred during follow-up and we cannot adequately explain their pathological processes.

There is emerging evidence that stopping smoking prior to any type of surgery decreases the potential for surgical complications\[[@B156]\]. All pharmacotherapies used for smoking cessation demonstrate adverse events, albeit in differing conditions and severity\[[@B4]\]. However, given the cardiovascular concerns discussed above, and the fact that cardiovascular events are increased during the perioperative period\[[@B157]\], it is reasonable to consider other behavioral or pharmacotherapies for at-risk patients undergoing major surgeries.

Conclusions
===========

This review demonstrates that NRT is associated with adverse effects that may be discomforting for the patient but are not life-threatening. Given the long-term benefits of smoking cessation over continued smoking, concern about NRT related adverse events should be balanced against the benefits of cessation. Clinicians should monitor for side effects that may worsen underlying conditions, such as insomnia in patients with depression, and consider additional or alternative treatments. Given the benefits of smoking cessation and the important role of NRT in achieving this goal, efforts should be made to counsel patients on the most common side effects and strategies should be developed to deal with them.
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